Skip to main content
. Author manuscript; available in PMC: 2018 Feb 28.
Published in final edited form as: J Mater Chem B. 2017 Jan 10;5(8):1574–1584. doi: 10.1039/C6TB02269C

Figure 3.

Figure 3

viability of bmdm with cytokine and microparticle treatment. (a) viability of bmdm as measured by mtt assay upon stimulation with 0.3 ng/ml lps and 1 ng/ ml ifnγ, 0.3ng/ml lps, 20 ng/ml il-4 and 20 ng/ml il-13, or left untreated. (b) viability of bmdm treated with different amounts (% surface coverage) of plga or cd200-plga microparticles. viability of bmdm incubated with 7μm (c) or 28μm (d) plga microparticles with different surface modifications and stimulated with cytokines at the same concentrations described in (a). data represents mean ± sem of n=3. * denotes p<0.05.